Zhitong Finance App News, Ganli Pharmaceutical (603087.SH) announced that the GLR1075 injection independently developed by the company is undergoing phase I clinical trials in China, and recently successfully completed the administration of the first test subject.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.